References
- Kadkhoda K. Post-adenoviral-based COVID-19 vaccines thrombosis: a proposed mechanism. J Thromb Haemost. 2021 Apr 26;19(7):1831–1832. Epub ahead of print. PMID: 33904251.
- Østergaard SD, Schmidt M, Horváth-Puhó E, et al. Thromboembolism and the Oxford-AstraZeneca COVID-19 vaccine: side-effect or coincidence? Lancet. 2017;397(10283):1441–1443.
- Tobaiqy M, Elkout H, MacLure K. Analysis of thrombotic adverse reactions of COVID-19 AstraZeneca vaccine reported to EudraVigilance database. Vaccines (Basel). 2021;9(4):393.
- Greinacher A, Thiele T, Warkentin TE, et al. Thrombotic thrombocytopenia after ChAdOx1 nCov-19 vaccination. N Engl J Med. 2021 Jun 3;384(22):2092–2101.
- Kragholm K, Sessa M, Mulvad T, et al. Thrombocytopenia after COVID-19 vaccination. J Autoimmun. 2021;123:102712.
- Douxfils J, Favresse J, Dogné JM, et al. Hypotheses behind the very rare cases of thrombosis with thrombocytopenia syndrome after SARS-CoV-2 vaccination. Thromb Res. 2021 Jul;203:163–171.
- Calcaterra G, Bassareo PP, Barilla’ F, et al. Concerning the unexpected prothrombotic state following some coronavirus disease 2019 vaccines. J Cardiovasc Med (Hagerstown). 2021;6. doi: 10.2459/JCM.0000000000001232.
- Rosell A, Havervall S, von Meijenfeldt F, et al. Patients with COVID-19 have elevated levels of circulating extracellular vesicle tissue factor activity that is associated with severity and mortality. Arterioscler Thromb Vasc Biol. 2020;41(2):878–882.
- Bautista-Vargas M, Bonilla-Abadía F, Cañas CA. Potential role for tissue factor in the pathogenesis of hypercoagulability associated with in COVID-19. J Thromb Thrombolysis. 2020;50(3):479–483.
- Visseren FL, Bouwman JJ, Bouter KP, et al. Procoagulant activity of endothelial cells after infection with respiratory viruses. Thromb Haemost. 2000;84(2):319–324.
- Letarov AV, Babenko VV, Kulikov EE. Free SARS-CoV-2 spike protein S1 particles may play a role in the pathogenesis of COVID-19 infection. Biochemistry (Mosc). 2021;86(3):257–261.
- Mälarstig A, Tenno T, Johnston N, et al. Genetic variations in the tissue factor gene are associated with clinical outcome in acute coronary syndrome and expression levels in human monocytes. Arterioscler Thromb Vasc Biol. 2005;25(12):2667–2672.
- Opstad TB, Pettersen AA, Weiss T, et al. Gender differences of polymorphisms in the TF and TFPI genes, as related to phenotypes in patients with coronary heart disease and type-2 diabetes. Thromb J. 2010;8(1):7.
- Potaczek DP, Pieculewicz M, Mazur M, et al. Tissue factor +5466A>G polymorphism predicts plasma TF levels in subjects with cryptogenic ischaemic stroke. Thromb Haemost. 2009;102(1):173–175.
- Rauova L, Tutwiler V, Hyun Sook Ahn H, et al. THE two phases of Heparin-Induced Thrombocytopenia (HIT): early Monocyte/Tissue Factor (TF) phase and late platelet phase. Blood. 2012;120(21):270.
- Jayachandran M, Sanzo A, Owen WG, et al. Estrogenic regulation of tissue factor and tissue factor pathway inhibitor in platelets. Am J Physiol Heart Circ Physiol. 2005;289(5):H1908–16.
- Dulicek P, Ivanova E, Kostal M, et al. Analysis of risk factors of stroke and venous thromboembolism in females with oral contraceptives use. Clin Appl Thromb Hemost. 2018 Jul;24(5):797–802.